A Trial to Compare Antibacterial vs. Placebo Mouthwash to Reduce the Incidence of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men (MSM) Taking HIV Pre-Exposure Prophylaxis (PrEP)

NCT ID: NCT03881007

Last Updated: 2021-05-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

343 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-03

Study Completion Date

2020-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study involves a randomized placebo controlled trial that aims to assess if a mouthwash (Listerine cool mint, LCM) is able to reduce the cumulative incidence of gonorrhoea (Ng), chlamydia (Ct) and syphilis in men who have sex with men and receiving preexposure prophylaxis (PrEP) at the Institute of Tropical Medicine (ITM).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study aims to assess if there is a difference in the incidence rate of gonorrhea, chlamydia and syphilis detected at any site whilst individuals are on daily and pre/post sex Listerine cool mint (LCM) vs. placebo mouthwash.

The study has a double-blind, cross-over design, in which subjects will be screened at the ITM and, if eligible, will be enrolled and randomized to group 1 (LCM) or group 2 (placebo). After 3 months, a crossover will occur and subjects will switch to the other intervention. Each participant will therefore be enrolled for 6 months (2 x 3 months, no wash out period).

Subjects will be recruited from the existing PrEP cohort at the Institute of Tropical Medicine Antwerp. A total of 320 subjects will be recruited (160 in each arm).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sexually Transmitted Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LCM, then placebo

Mouthwash with LCM for 3 months followed by mouthwash with placebo for 3 months.

Group Type EXPERIMENTAL

Mouthwash with LCM

Intervention Type OTHER

Subjects will mouthwash daily with LCM and before/after sex

Mouthwash with placebo

Intervention Type OTHER

Subjects will mouthwash daily with placebo and before/after sex

Placebo, then LCM

Mouthwash with placebo for 3 months followed by mouthwash with LCM for 3 months

Group Type EXPERIMENTAL

Mouthwash with LCM

Intervention Type OTHER

Subjects will mouthwash daily with LCM and before/after sex

Mouthwash with placebo

Intervention Type OTHER

Subjects will mouthwash daily with placebo and before/after sex

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mouthwash with LCM

Subjects will mouthwash daily with LCM and before/after sex

Intervention Type OTHER

Mouthwash with placebo

Subjects will mouthwash daily with placebo and before/after sex

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men aged 18 or more
* Enrolled in Belgian PrEP program at ITM
* Has had sex with another man in the previous year
* Has had a symptomatic or asymptomatic STI (Ct/Ng/syphilis) in the previous 2 years
* Willing to be enrolled in the cohort for 6 months and attend 3 monthly follow up visits
* Willing to comply with the mouthwash study schema and willing to ask their casual partners to mouthwash pre- and post-sex
* Prepared to fill out the online diary once a week
* Able and willing to provide written informed consent

Exclusion Criteria

* Currently using a mouthwash and unwilling to cease use of this mouthwash
* Enrolment in another interventional trial
* Tests HIV positive at screening
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institute of Tropical Medicine, Belgium

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chris Kenyon, MD

Role: PRINCIPAL_INVESTIGATOR

Institute of Tropical Medicine Antwerp

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institute of Tropical Medicine

Antwerp, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

References

Explore related publications, articles, or registry entries linked to this study.

Akomoneh EA, Laumen JGE, Abdellati S, Van Dijck C, Vanbaelen T, Britto XB, Manoharan-Basil SS, Kenyon C. The Discovery of Oropharyngeal Microbiota with Inhibitory Activity against Pathogenic Neisseria gonorrhoeae and Neisseria meningitidis: An In Vitro Study of Clinical Isolates. Microorganisms. 2022 Dec 16;10(12):2497. doi: 10.3390/microorganisms10122497.

Reference Type DERIVED
PMID: 36557750 (View on PubMed)

Van Dijck C, Tsoumanis A, Rotsaert A, Vuylsteke B, Van den Bossche D, Paeleman E, De Baetselier I, Brosius I, Laumen J, Buyze J, Wouters K, Lynen L, Van Esbroeck M, Herssens N, Abdellati S, Declercq S, Reyniers T, Van Herrewege Y, Florence E, Kenyon C. Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis (PReGo): a randomised, placebo-controlled, crossover trial. Lancet Infect Dis. 2021 May;21(5):657-667. doi: 10.1016/S1473-3099(20)30778-7. Epub 2021 Mar 4.

Reference Type DERIVED
PMID: 33676596 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ITM201801

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

SPL7013 Gel - Male Tolerance Study
NCT00370357 COMPLETED PHASE1
A Study of BufferGel in Women
NCT00000927 COMPLETED PHASE1
Study of UC-781 Vaginal Microbicide
NCT00132444 COMPLETED PHASE1